Transcriptional control of Gad2

Transcription

Volumn 3, Issue 2, 2012, Pages 68-72

  Pan, Zhizhong Z ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

GABA, GAD65, TATA less promoters, cAMP response element binding protein (CREB), histone acetylation, chronic pain

Indexed keywords

4 AMINOBUTYRIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; HISTONE H3; TATA BINDING PROTEIN ASSOCIATED FACTOR;

4 AMINOBUTYRIC ACID RELEASE; ARTICLE; CHROMATIN STRUCTURE; DNA SEQUENCE; DOWN REGULATION; EPIGENETICS; GABAERGIC TRANSMISSION; GENE; GENE CONTROL; GENE LOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUTAMATE DECARBOXYLASE 2 GENE; GLUTAMATE DECARBOXYLASE 65 GENE; HISTONE ACETYLATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PROMOTER REGION; PROTEIN FUNCTION; SYNAPTIC INHIBITION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION;

EID: 84862737927     PISSN: 21541264     EISSN: 21541272     Source Type: Journal    
DOI: 10.4161/trns.19511     Document Type: Article

References (39)

1. McBain CJ, Fisahn A. Interneurons unbound. Nat Rev Neurosci 2001; 2:11-23. PMID:11253355; http://dx.doi.org/10.1038/35049047.
2. Erlander MG, Tillakaratne NJ, Feldblum S, Patel N, Tobin AJ. Two genes encode distinct glutamate decarboxylases. Neuron 1991; 7:91-100. PMID:2069816; http://dx.doi.org/10.1016/0896-6273(91)90077-D.
3. Betley JN, Wright CV, Kawaguchi Y, Erdélyi F, Szabó G, Jessell TM, et al. Stringent specificity in the construction of a GABAergic presynaptic inhibitory circuit. Cell 2009; 139:161-174. PMID:19804761; http://dx.doi.org/10.1016/j.cell.2009.08.027.
4. Soghomonian JJ, Martin DL. Two isoforms of glutamate decarboxylase: why? Trends Pharmacol Sci 1998; 19:500-505. PMID:9871412; http://dx.doi.org/10.1016/S0165-6147(98)01270-X.
5. Tian N, Petersen C, Kash S, Baekkeskov S, Copenhagen D, Nicoll R. The role of the synthetic enzyme GAD65 in the control of neuronal gammaaminobutyric acid release. Proc Natl Acad Sci USA 1999; 96:12911-12916. PMID:10536022; http://dx.doi.org/10.1073/pnas.96.22.12911.
6. Kash SF, Johnson RS, Tecott LH, Noebels JL, Mayfield RD, Hanahan D, et al. Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci USA 1997; 94:14060-14065. PMID:9391152; http://dx.doi.org/10.1073/pnas.94.25.14060.
7. Pinal CS, Cortessis V, Tobin AJ. Multiple elements regulate GAD65 transcription. Dev Neurosci 1997; 19:465-475. PMID:9445084; http://dx.doi.org/10.1159/000111244.
8. Skak K, Michelsen BK. The TATA-less rat GAD65 promoter can be activated by Sp1 through non-consensus elements. Gene 1999; 236:231-41. PMID:10452943; http://dx.doi.org/10.1016/S0378-1119(99)00286-3.
9. Ong CT, Corces VG. Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat Rev Genet 2011; 12:283-293. PMID:21358745; http://dx.doi.org/10.1038/nrg2957.
10. Kim TK, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, et al. Widespread transcription at neuronal activity-regulated enhancers. Nature 2010; 465:182-187. PMID:20393465; http://dx.doi.org/10.1038/nature09033.
11. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007; 39:311-318. PMID:17277777; http://dx.doi.org/10.1038/ng1966.
12. McClung CA, Nestler EJ. Regulation of gene expression and cocaine reward by CREB and DeltaFosB. Nat Neurosci 2003; 6:1208-1215. PMID:14566342; http://dx.doi.org/10.1038/nn1143.
13. Pham TA, Rubenstein JL, Silva AJ, Storm DR, Stryker MP. The CRE/CREB pathway is transiently expressed in thalamic circuit development and contributes to refinement of retinogeniculate axons. Neuron 2001; 31:409-420. PMID:11516398; http://dx.doi.org/10.1016/S0896-6273(01)00381-6.
14. Barco A, Alarcon JM, Kandel ER. Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture. Cell 2002; 108:689-703. PMID:11893339; http://dx.doi.org/10.1016/S0092-8674(02)00657-8.
15. Sánchez-Huertas C, Rico B. CREB-Dependent Regulation of GAD65 Transcription by BDNF/TrkB in Cortical Interneurons. Cereb Cortex 2011; 21:777-788. PMID:20739478; http://dx.doi.org/10.1093/cercor/bhq150.
16. Finkbeiner S, Tavazoie SF, Maloratsky A, Jacobs KM, Harris KM, Greenberg ME. CREB: a major mediator of neuronal neurotrophin responses. Neuron 1997; 19:1031-1047. PMID:9390517; http://dx.doi.org/10.1016/S0896-6273(00)80395-5.
17. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8:355-367. PMID:17453016; http://dx.doi.org/10.1038/nrn2132.
18. Marty S, Wehrlé R, Sotelo C. Neuronal activity and brain-derived neurotrophic factor regulate the density of inhibitory synapses in organotypic slice cultures of postnatal hippocampus. J Neurosci 2000; 20:8087-8095. PMID:11050130.
19. Hong EJ, McCord AE, Greenberg ME. A biological function for the neuronal activity-dependent component of Bdnf transcription in the development of cortical inhibition. Neuron 2008; 60:610-624. PMID:19038219; http://dx.doi.org/10.1016/j.neuron.2008.09.024.
20. Rico B, Xu B, Reichardt LF. TrkB receptor signaling is required for establishment of GABAergic synapses in the cerebellum. Nat Neurosci 2002; 5:225-233. PMID:11836532; http://dx.doi.org/10.1038/nn808.
21. Sakata K, Woo NH, Martinowich K, Greene JS, Schloesser RJ, Shen L, et al. Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortex. Proc Natl Acad Sci USA 2009; 106:5942-5947. PMID:19293383; http://dx.doi.org/10.1073/pnas.0811431106.
22. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403:41-45. PMID:10638745; http://dx.doi.org/10.1038/47412.
23. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293:1074-1080. PMID:11498575; http://dx.doi.org/10.1126/science.1063127.
24. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128:693-705. PMID:17320507; http://dx.doi.org/10.1016/j.cell.2007.02.005.
25. MacDonald JL, Roskams AJ. Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation. Prog Neurobiol 2009; 88:170-183. PMID:19554713; http://dx.doi.org/10.1016/j.pneurobio.2009.04.002.
26. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009; 459:55-60. PMID:19424149; http://dx.doi.org/10.1038/nature07925.
27. Zhang Z, Cai YQ, Zou F, Bie B, Pan ZZ. Epigenetic suppression of GAD65 expression mediates persistent pain. Nat Med 2011; 17:1448-1455. PMID:21983856; http://dx.doi.org/10.1038/nm.2442.
28. Gräff J, Kim D, Dobbin MM, Tsai LH. Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiol Rev 2011; 91:603-649. PMID:21527733; http://dx.doi.org/10.1152/physrev.00012.2010.
29. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11:726-734. PMID:21941284; http://dx.doi.org/10.1038/nrc3130.
30. Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes and therapies. Lancet Neurol 2009; 8:1056-1072. PMID:19833297; http://dx.doi.org/10.1016/S1474-4422(09)70262-5.
31. Wong CG, Bottiglieri T, Snead OC, 3rd. GABA, gammahydroxybutyric acid and neurological disease. Ann Neurol 2003; 54:3-12. PMID:12891648; http://dx.doi.org/10.1002/ana.10696.
32. Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov 2011; 10:685-697. PMID:21799515; http://dx.doi.org/10.1038/nrd3502.
33. Munro G, Ahring PK, Mirza NR. Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. Trends Pharmacol Sci 2009; 30:453-459. PMID:19729210; http://dx.doi.org/10.1016/j.tips.2009.06.004.
34. Benes FM, Lim B, Matzilevich D, Walsh JP, Subburaju S, Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci USA 2007; 104:10164-10169. PMID:17553960; http://dx.doi.org/10.1073/pnas.0703806104.
35. Elizalde N, García-García AL, Totterdell S, Gendive N, Venzala E, Ramirez MJ, et al. Sustained stress-induced changes in mice as a model for chronic depression. Psychopharmacology (Berl) 2010; 210:393-406. PMID:20401750; http://dx.doi.org/10.1007/s00213-010-1835-6.
36. Kubo K, Nishikawa K, Ishizeki J, Hardy-Yamada M, Yanagawa Y, Saito S. Thermal hyperalgesia via supraspinal mechanisms in mice lacking glutamate decarboxylase 65. J Pharmacol Exp Ther 2009; 331:162-169. PMID:19571163; http://dx.doi.org/10.1124/jpet.109.156034.
37. Vit JP, Ohara PT, Sundberg C, Rubi B, Maechler P, Liu C, et al. Adenovector GAD65 gene delivery into the rat trigeminal ganglion produces orofacial analgesia. Mol Pain 2009; 5:42. PMID:19656360; http://dx.doi.org/10.1186/1744-8069-5-42.
38. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16:669-694. PMID:12269861.
39. Fleming J, Chetty M. Therapeutic monitoring of valproate in psychiatry: how far have we progressed? Clin Neuropharmacol 2006; 29:350-360. PMID:17095899; http://dx.doi.org/10.1097/01.WNF.0000228209.69524.E8.